Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Residual body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    226 result(s) found for: Residual body. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001965-17 Sponsor Protocol Number: AITT2013/5 Start Date*: 2013-09-26
    Sponsor Name:Debreceni Egyetem Orvos- és Egészségtudományi Centrum Aneszteziológiai és Intenzív Terápiás Tanszék
    Full Title: Incidence of postoperative residual neuromuscular blockade following the administration of rocuronium: A randomized placebo controlled study.
    Medical condition: The effect of sugammadex and neostigmin on postoperative residual neuromuscular blockade will be investigated, therefore the patients suffering from various conditions undergoing surgery in general...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001683-22 Sponsor Protocol Number: 1/2011AITT Start Date*: 2011-06-10
    Sponsor Name:University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy
    Full Title: Reversal of residual rocuronium neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dose-finding study
    Medical condition: The effect of sugammadex dose on residual neuromuscular blockade will be investigated, therefore patients suffering from various conditions undergoing surgery in general anaesthesia with muscle rel...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004666-34 Sponsor Protocol Number: AITT2014/1 Start Date*: 2014-03-17
    Sponsor Name:University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy
    Full Title: Reversal of vecuronium induced residual neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dosefinding study
    Medical condition: The effect of sugammadex dose on residual neuromuscular blockade will be investigated, therefore patients suffering from various conditions undergoing surgery in general anaesthesia with muscle rel...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000259-14 Sponsor Protocol Number: 1/2012AITT Start Date*: 2012-08-31
    Sponsor Name:University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy
    Full Title: Reversal of residual pipecuronium neuromuscular block using sugammadex: a randomized, double-blind, placebo controlled, dosefinding study
    Medical condition: The effect of sugammadex dose on residual neuromuscular blockade will be investigated, therefore patients suffering from various conditions undergoing surgery in general anaesthesia with muscle rel...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016857-16 Sponsor Protocol Number: AGO/2009/010 Start Date*: 2010-06-09
    Sponsor Name:University Hospital Ghent
    Full Title: Dose finding study for effective reversal of a moderate rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients
    Medical condition: Morbidly obese patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002739-40 Sponsor Protocol Number: GLP1_glucose_control Start Date*: 2017-07-27
    Sponsor Name:Radboud university medical center
    Full Title: Beta cell imaging in type 1 diabetes with stable near-normal and unstable glucose control using PET
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003251-11 Sponsor Protocol Number: DIABGAD-1 Start Date*: 2012-11-21
    Sponsor Name:Linköping university
    Full Title: Pilot Trial to preserve residual insulin secretion in children and adolescents with recent onset Type 1 diabetes by using GAD-antigen (Diamyd) therapy in combination with Vitamin D and Ibuprofen .
    Medical condition: Type 1 diabetes in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002094-36 Sponsor Protocol Number: D3250C00038 Start Date*: 2016-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004010-34 Sponsor Protocol Number: ClaTBI/2019 Start Date*: 2020-05-18
    Sponsor Name:Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach
    Full Title: Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukem...
    Medical condition: Accute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000687-41 Sponsor Protocol Number: LEVOLIO Start Date*: 2016-08-01
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DI MODENA
    Full Title: COMBINED SUBSTITUTIVE THERAPY WITH LEVOTHYROXINE AND LIOTHYRONINE IN THYROIDECTOMIZED PATIENTS: EFFECTS ON PERIPHERICAL TISSUES. A PROSPECTIVE RANDOMIZED CONTROLLED DOUBLE BLIND STUDY.
    Medical condition: Post-surgical hypothyroidism in substitutive therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10036429 Postsurgical hypothyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000057-37 Sponsor Protocol Number: ABBA-2014 Start Date*: 2014-04-30
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A B2-agonist as a CFTR activator in CF
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001852-41 Sponsor Protocol Number: GLP1-FMT Start Date*: 2022-09-06
    Sponsor Name:Radboud university medical center
    Full Title: BetaFIT study: Beta cell imaging after Faecal mIcrobiota Transplantation
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003151-62 Sponsor Protocol Number: BENOS Start Date*: 2014-10-09
    Sponsor Name:Infectopharm Arzneimittel und Consilium GmbH
    Full Title: A randomised, two-period two-stage cross-over study on the relative bioavailability of two different formulations of single doses of noscapine (phase I/IV, open-label) in healthy volunteers (fasted...
    Medical condition: healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002012-12 Sponsor Protocol Number: BENOS-2-L Start Date*: 2021-12-13
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: A randomised, two-period two-stage cross-over study on the relative bioavailability of two different liquid formulations of single noscapine doses (phase I/IV, open-label) in healthy volunteers (fa...
    Medical condition: Healthy controls
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003113-17 Sponsor Protocol Number: MEU17/361 Start Date*: 2018-11-09
    Sponsor Name:The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study)
    Full Title: A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000404-35 Sponsor Protocol Number: 80519 Start Date*: 2022-07-26
    Sponsor Name:AMC, Cardiovascular Sciences
    Full Title: Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes?
    Medical condition: Inflammation in patients with type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002607-33 Sponsor Protocol Number: ANRSHC31SOFTRIH Start Date*: 2014-02-17
    Sponsor Name:INSERM-ANRS
    Full Title: Pilot study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in NS3/4A protease inhibitor-experienced subjects with HCV genotype 1 infection an...
    Medical condition: Coinfection with HCV genotype 1 and HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004629-96 Sponsor Protocol Number: S-20130147 Start Date*: 2014-06-13
    Sponsor Name:Department of Nuclear Medicine, Odense University Hospital
    Full Title: Diagnostic Modalities in Nuclear Medicine in Well-Differentiated Thyroid Cancer
    Medical condition: Well-differentiated Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023479-24 Sponsor Protocol Number: 01/2010 Start Date*: 2011-02-03
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Effect of Interleukin-1 receptor antagonist on insulin sensitivity in subjects with type 1 diabetes mellitus.
    Medical condition: diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003179-12 Sponsor Protocol Number: MN0511_1 Start Date*: 2012-01-09
    Sponsor Name:University Hospital of Wuerzburg, Medical Director
    Full Title: Mineralocorticoid Receptor antagonists in End stage reNal DiseAse
    Medical condition: Hemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:48:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA